| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 42.074 | 42.031 | 41.992 | 41.846 | 91.718 | 96.010 | 120.991 | 121.777 | 160.090 | 235.807 |
| Total Income - EUR | 42.151 | 42.104 | 42.073 | 41.965 | 91.856 | 96.105 | 121.410 | 121.911 | 160.380 | 238.804 |
| Total Expenses - EUR | 23.422 | 17.331 | 24.677 | 24.331 | 39.635 | 16.210 | 26.192 | 36.601 | 25.681 | 34.418 |
| Gross Profit/Loss - EUR | 18.728 | 24.774 | 17.395 | 17.634 | 52.221 | 79.895 | 95.219 | 85.310 | 134.698 | 204.386 |
| Net Profit/Loss - EUR | 15.198 | 20.453 | 13.922 | 17.215 | 51.303 | 78.829 | 94.047 | 84.293 | 112.108 | 169.409 |
| Employees | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Check the financial reports for the company - Atlaspharm S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 73.211 | 72.205 | 71.533 | 71.004 | 85.907 | 79.030 | 70.798 | 65.230 | 64.108 | 63.776 |
| Current Assets | 33.979 | 36.393 | 13.347 | 31.265 | 25.642 | 76.251 | 135.795 | 168.079 | 241.117 | 317.262 |
| Inventories | 0 | 916 | 1.692 | 21.382 | 0 | 0 | 0 | 0 | 0 | 902 |
| Receivables | 0 | 0 | 0 | 0 | 47 | 70 | 894 | 515 | 3.983 | 610 |
| Cash | 33.979 | 35.477 | 11.655 | 9.884 | 25.595 | 76.181 | 134.901 | 167.563 | 237.134 | 315.750 |
| Shareholders Funds | 103.728 | 50.012 | 63.088 | 79.145 | 100.992 | 129.209 | 200.176 | 187.650 | 248.648 | 292.551 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 3.461 | 58.586 | 21.792 | 23.124 | 10.556 | 26.072 | 7.423 | 45.659 | 56.643 | 88.487 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "7112 - 7112" | |||||||||
| CAEN Financial Year |
7112
|
|||||||||
Comments - Atlaspharm S.r.l.